Market Cap 407.87M
Revenue (ttm) 228.61M
Net Income (ttm) -82.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 486.50
Profit Margin -35.95%
Debt to Equity Ratio 0.00
Volume 609,700
Avg Vol 90,972
Day's Range N/A - N/A
Shares Out 20.68M
Stochastic %K 43%
Beta 0.62
Analysts Hold
Price Target $10.67

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty p...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 353 0 166 99020
Address:
One Central Plaza, 5th Floor 36 Dame Street, Dublin, Ireland
jjinhispjs
jjinhispjs Oct. 27 at 2:54 PM
$AMRN Another great paper about V!! https://www.linkedin.com/posts/amelia-carro-hevia-90534468_ipe-in-normolipidemic-individuals-activity-7386906742317629440-kHs3?utm_medium=ios_app&rcm=ACoAAAnXY8IBr2c8fq0b6sSTKlIv18Q5vhKXyo8&utm_source=social_share_send&utm_campaign=copy_link
0 · Reply
1ightningscalps
1ightningscalps Oct. 27 at 2:49 PM
1ightning® Options Trade Alert (Actionable) | Buy $AMRN Nov 21 $20 Call | Enter: $2.51 Exit: $3.54 | Profit: 41.01% ROI | https://1ightning.com
0 · Reply
MorrisBorris2Duex
MorrisBorris2Duex Oct. 27 at 2:34 PM
$AMRN 74k sh in 1 hr. of trading. gap filled on the up side. lets roll!!
0 · Reply
Logical95
Logical95 Oct. 27 at 2:22 PM
$AMRN The company who everyone on here thought would buy us out (Novartis) just forked over 12 billion in cash to BO another small bio. This year they have bought Regulus, Anthos, and MorphoSys......now Avidity. Seems like there won't be too much $$ leftover for us.....I want at least 5 billion for V and our IP. 100 a share
1 · Reply
Opster216
Opster216 Oct. 27 at 2:04 PM
$AMRN It was clear that for at least this morning the positive news would not increase the price as it was out for over an hour and very little buying this morning premarket. I added a few shares just in case.
1 · Reply
Ilikebeinggreen
Ilikebeinggreen Oct. 27 at 2:01 PM
$AMRN Incredibly positive news. Ignore the manipulation. It will correct - likely in a few hours.
0 · Reply
Finitemaf
Finitemaf Oct. 27 at 1:59 PM
$AMRN adding for earnings… I’m a glutton for punishment. Good luck longs. I think this is the earnings we’ve been waiting for. The tides are turning!
0 · Reply
yevrag
yevrag Oct. 27 at 1:58 PM
$AMRN only this pos can go down on decent news! lol
0 · Reply
Bonnydick
Bonnydick Oct. 27 at 1:46 PM
$AMRN Down on good news. Classic.
0 · Reply
ians
ians Oct. 27 at 1:42 PM
$AMRN Truth. 👍 Now, how about the FDA add to Vascepa's label that it's the most cost-effective in reducing CVD of all the approved options. ☘️💎 “Fenofibrate did not reduce cardiovascular disease morbidity or mortality in two large, randomized controlled trials of patients with type 2 diabetes mellitus.” i “Risk for rhabdomyolysis is increased when fibrates are co-administered with a statin. Avoid concomitant use unless the benefit of further alterations in TG levels is likely to outweigh the increased risk of this drug combination.” ii “Fenofibrates are now indicated for the reduction in elevated LDL-C in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible.” iii https://finance.yahoo.com/news/amarin-issues-statement-supporting-fda-120000520.html
0 · Reply
Latest News on AMRN
Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 2:06 PM EDT - 3 months ago

Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript


Amarin Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 7:00 AM EDT - 3 months ago

Amarin Reports Second Quarter 2025 Financial Results


Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript

May 7, 2025, 11:01 AM EDT - 6 months ago

Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript


Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 9, 2025, 7:30 AM EDT - 7 months ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change


Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 10:30 AM EDT - 8 months ago

Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript


Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 16, 2024, 7:00 AM EST - 11 months ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy


Amarin Appoints Peter Fishman Chief Financial Officer

Dec 13, 2024, 9:00 AM EST - 11 months ago

Amarin Appoints Peter Fishman Chief Financial Officer


Top 3 Health Care Stocks You'll Regret Missing In Q4

Nov 19, 2024, 7:52 AM EST - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

SLN TERN


Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 12:28 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript


Amarin Board of Directors Announces CEO Transition

Jun 4, 2024, 7:30 AM EDT - 1 year ago

Amarin Board of Directors Announces CEO Transition


Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 10:18 AM EST - 1 year ago

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript


Amarin Chairman & CEO Issue Letter to Shareholders

Jan 22, 2024, 7:30 AM EST - 1 year ago

Amarin Chairman & CEO Issue Letter to Shareholders


Amarin: Sarissa Is Giving Me Hope Again

Jan 15, 2024, 3:06 AM EST - 1 year ago

Amarin: Sarissa Is Giving Me Hope Again


jjinhispjs
jjinhispjs Oct. 27 at 2:54 PM
$AMRN Another great paper about V!! https://www.linkedin.com/posts/amelia-carro-hevia-90534468_ipe-in-normolipidemic-individuals-activity-7386906742317629440-kHs3?utm_medium=ios_app&rcm=ACoAAAnXY8IBr2c8fq0b6sSTKlIv18Q5vhKXyo8&utm_source=social_share_send&utm_campaign=copy_link
0 · Reply
1ightningscalps
1ightningscalps Oct. 27 at 2:49 PM
1ightning® Options Trade Alert (Actionable) | Buy $AMRN Nov 21 $20 Call | Enter: $2.51 Exit: $3.54 | Profit: 41.01% ROI | https://1ightning.com
0 · Reply
MorrisBorris2Duex
MorrisBorris2Duex Oct. 27 at 2:34 PM
$AMRN 74k sh in 1 hr. of trading. gap filled on the up side. lets roll!!
0 · Reply
Logical95
Logical95 Oct. 27 at 2:22 PM
$AMRN The company who everyone on here thought would buy us out (Novartis) just forked over 12 billion in cash to BO another small bio. This year they have bought Regulus, Anthos, and MorphoSys......now Avidity. Seems like there won't be too much $$ leftover for us.....I want at least 5 billion for V and our IP. 100 a share
1 · Reply
Opster216
Opster216 Oct. 27 at 2:04 PM
$AMRN It was clear that for at least this morning the positive news would not increase the price as it was out for over an hour and very little buying this morning premarket. I added a few shares just in case.
1 · Reply
Ilikebeinggreen
Ilikebeinggreen Oct. 27 at 2:01 PM
$AMRN Incredibly positive news. Ignore the manipulation. It will correct - likely in a few hours.
0 · Reply
Finitemaf
Finitemaf Oct. 27 at 1:59 PM
$AMRN adding for earnings… I’m a glutton for punishment. Good luck longs. I think this is the earnings we’ve been waiting for. The tides are turning!
0 · Reply
yevrag
yevrag Oct. 27 at 1:58 PM
$AMRN only this pos can go down on decent news! lol
0 · Reply
Bonnydick
Bonnydick Oct. 27 at 1:46 PM
$AMRN Down on good news. Classic.
0 · Reply
ians
ians Oct. 27 at 1:42 PM
$AMRN Truth. 👍 Now, how about the FDA add to Vascepa's label that it's the most cost-effective in reducing CVD of all the approved options. ☘️💎 “Fenofibrate did not reduce cardiovascular disease morbidity or mortality in two large, randomized controlled trials of patients with type 2 diabetes mellitus.” i “Risk for rhabdomyolysis is increased when fibrates are co-administered with a statin. Avoid concomitant use unless the benefit of further alterations in TG levels is likely to outweigh the increased risk of this drug combination.” ii “Fenofibrates are now indicated for the reduction in elevated LDL-C in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible.” iii https://finance.yahoo.com/news/amarin-issues-statement-supporting-fda-120000520.html
0 · Reply
Family23
Family23 Oct. 27 at 1:21 PM
0 · Reply
raylin
raylin Oct. 27 at 1:11 PM
$AMRN Getr Done Denner!!
0 · Reply
CaptBeer
CaptBeer Oct. 27 at 1:07 PM
$AMRN https://www.linkedin.com/posts/michael-everts-34799334_thomas-dayspring-md-facp-fnla-you-once-activity-7388561730752307200-4fIv?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAdDmycBzT_CwLIulyFqANe8SLMF4KH2Odo
1 · Reply
WiseSolution
WiseSolution Oct. 27 at 1:00 PM
$AMRN Amarin said the change should shift prescribing toward FDA-approved, outcome-proven therapies such as VASCEPA (icosapent ethyl).
0 · Reply
SanDiegoLiving
SanDiegoLiving Oct. 27 at 12:57 PM
$AMRN 💰 FDA JUST UNLOCKED A $5–8B OPPORTUNITY FOR AMRN 🚀 | THE NUMBERS BEHIND THE SHIFT 🧠 The FDA’s fibrate ruling just rewired the lipid market — and Amarin’s latest Corporate Overview 📊 spells out the upside. 🇺🇸 United States: Over 12M fibrate and 3M EPA+DHA prescriptions are written each year — nearly 15M total from drugs now proven to offer no cardiovascular benefit. With Vascepa priced around $1K$1.2K per patient annually, even a 20 % conversion equals $3B in new revenue. 🤯 A 30–40 % shift could expand that to $4.5–$6B TAM in the U.S. alone. 🌍 Europe: Roughly 245M fibrate doses are dispensed yearly (~2M patients). Converting just a portion adds another $1.5–$2B opportunity. 📈 Takeaway: The FDA confirmed what the Corporate Overview visual shows 📸 — fibrates ❌ failed event reduction, while Vascepa/Vazkepa ✅ achieved a 25 % RRR across 8,000+ patients. That’s a $5$8B global gap 🌐 now wide open for Amarin to capture & control in cardio care.
0 · Reply
TheParallel
TheParallel Oct. 27 at 12:48 PM
0 · Reply
DoMoreCharity
DoMoreCharity Oct. 27 at 12:36 PM
$AMRN 💪🏻💪🏻💪🏻https://www.amarincorp.com/news-and-media/amarin-issues-statement-supporting-fdas-action-revise-labeling
0 · Reply
SanDiegoLiving
SanDiegoLiving Oct. 27 at 12:32 PM
$AMRN 🔥 FDA JUST CROWNED AMARIN 👑 | THE FIBRATE EMPIRE HAS FALLEN 🧠💰 The FDA just erased decades of dogma. Every fenofibrate drug now carries a bold warning: “Fenofibrate did not reduce cardiovascular disease morbidity or mortality.” 🚫 This landmark action, sparked by HealthyWomen’s petition and Amarin’s scientific comment, confirms what REDUCE-IT proved — only VASCEPA®/VAZKEPA® delivers clinically proven cardiovascular-event reduction. ❤️ 💰 11M+ fibrate prescriptions in 2023 are now obsolete. Even partial migration could add $500M+ yearly runway before global expansion . For acquirers, this turns Amarin into a regulatory-validated outcomes monopoly with global TAM leverage. 🔥 The FDA’s action officially separates proven cardiovascular therapies from legacy lipid drugs. Amarin now holds the only FDA-validated position in residual risk reduction. Full statement 👉 https://www.amarincorp.com/news-and-media/amarin-issues-statement-supporting-fdas-action-revise-labeling
2 · Reply
Blobbob
Blobbob Oct. 27 at 12:32 PM
$AMRN this is massive for the stock and combo pill with statins. 11 million scripts for fenofibrates in USA aline in 1 year and now not supported any longer by FDA. Pre market +9% right now. 21,48$. Up up and away
0 · Reply
Bonnydick
Bonnydick Oct. 27 at 12:24 PM
$AMRN Interesting. They appear to be pumping.
0 · Reply
Bulltrader988
Bulltrader988 Oct. 27 at 12:14 PM
$AMRN 👃👀 https://www.stocktitan.net/news/AMRN/amarin-issues-statement-supporting-fda-s-action-to-revise-labeling-9dn7diiznwip.html
1 · Reply
TraderRapp
TraderRapp Oct. 27 at 12:14 PM
$AMRN "We applaud the FDA’s decision to revise the labeling of fenofibrates (fibrates). The updated labeling now includes a clear statement on the lack of cardiovascular (CV) benefit, relevant safety data, and a refined indication as follows" This is more about medical negligence for all those scripts provider kept writing despite the medical literature. I wouldn't blame patient's for filing lawsuits, if they were prescribed fenofibrate the last 5 years.
0 · Reply